LUKAS SCHEIBLER
CIK 1651281 · Chief Research Officer · last filed 2023-12-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
43
Lifetime Open-Market Net
-$3.20M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Research Officer | 78,299 | $41.03 | $3.21M | -$3.20M | 26 | 2023-12-05 |
Recent Filings · Page 3 of 5
43 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-11 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −3,417 | -$205.0K | EDGAR |
| 2021-02-11 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −680 | -$32.4K | EDGAR |
| 2021-02-01 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +9,375 | $0 | EDGAR |
| 2020-12-09 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Exer (M) | +7,482 | $200.0K | EDGAR |
| 2020-02-12 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +9,375 | $0 | EDGAR |
| 2019-02-12 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-05-29 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Buy (P) | +2,935 | $59.8K | EDGAR |
| 2018-04-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-18 | — | Mixed | +1,413 | -$8.1K | |
| 2017-06-20 | — | Mixed | +1,364 | -$9.0K |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.